Cargando…

PB2128: CLINICAL CONSENSUS ON FIRST-LINE (1L) TREATMENTS FOR TRANSPLANT-INELIGIBLE (TIE) PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): DELPHI PANEL OF US HEMATOLOGISTS AND ONCOLOGISTS

Detalles Bibliográficos
Autores principales:	Fonseca, Rafael, Rossi, Adriana, Voelker, Jennifer, Homan, Trevor, Kaila, Shuchita, Medhekar, Rohan, Wilcock, Jessica, Karakusevic, Anna, Cochrane, James, Bridge, Daisy, Perry, Richard, Davies, Faith E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428952/ http://dx.doi.org/10.1097/01.HS9.0000975276.84488.94

Ejemplares similares

PB2110: PREDICTORS OF FRONTLINE (FL) DOUBLET OR TRIPLET REGIMEN USE AMONG TRANSPLANT-INELIGIBLE (TIE) PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) USING A MACHINE LEARNING APPROACH
por: Pianko, Matthew J., et al.
Publicado: (2023)

PB2351: ANXIETY AT THE HEMATOLOGIST
por: Trojan, S., et al.
Publicado: (2022)

PB1943: THE EFFECTS OF AN ONLINE CURRICULUM BASED APPROACH TO CME ON HEMATOLOGIST/ONCOLOGISTS’ ABILITY TO TREAT PATIENTS WITH BTK INHIBITORS FOR B-CELL MALIGNANCIES
por: Bomba, Sarah Elizabeth, et al.
Publicado: (2023)

PB2023: UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC).
por: Nuevo López, M. I., et al.
Publicado: (2022)

PB2128: CELL OF ORIGIN ACCORDING TO HANS LOGARITHM IS AN INDEPENDENT RISK FACTOR FOR DLBCL PATIENTS TREATED WITH R-CHOP: A REAL WORLD MOROCCAN EXPERIENCE
por: Mahtat, E. M., et al.
Publicado: (2022)

PB2163: BORTEZOMIB - CYCLOPHOSPHAMIDE – DEXAMETHASONE (VCD) REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) - EXPERIENCE FROM A RESOURCE CONSTRAINT SETTING IN SOUTH INDIA
por: Nameera, Rahmathullah Sulaimankutty, et al.
Publicado: (2023)

PB2705: PROFESSIONAL BURNOUT AMONG HEMATOLOGISTS AFTER THE OUTBREAK OF THE COVID-19 PANDEMIC AND ASSOCIATED FACTORS
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

PB2089: IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM-6
por: Girnius, Saulius K., et al.
Publicado: (2023)

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
por: Jakubowiak, Andrzej J, et al.
Publicado: (2022)

Applying spatial epidemiology to hematological disease using R: a guide for hematologists and oncologists
por: Kohno, Kei, et al.
Publicado: (2014)

Transfusion Practices in the Management of Sickle Cell Disease: A Survey of Florida Hematologists/Oncologists
por: Dunbar, Levette N., et al.
Publicado: (2012)

Physician approaches to drug shortages: Results of a national survey of pediatric hematologist/oncologists
por: Beck, Jill C, et al.
Publicado: (2017)

Second wave of COVID-19 – Not a matter of great concern for pediatric hematologist/oncologist
por: Bansal, Minakshi, et al.
Publicado: (2022)

Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support
por: Lee, Alfred Ian, et al.
Publicado: (2022)

A survey of pediatric hematologists/oncologists’ perspectives on single patient Expanded Access and Right to Try
por: Chapman, Carolyn Riley, et al.
Publicado: (2021)

Impact of legislation and public funding on oncofertility: a survey of Canadian, French and Moroccan pediatric hematologists/oncologists
por: Affdal, Aliya Oulaya, et al.
Publicado: (2020)

Current Status and Physicians’ Perspectives of Childhood Cancer Survivorship in Korea: A Nationwide Survey of Pediatric Hematologists/Oncologists
por: Lee, Ji Won, et al.
Publicado: (2023)

PB2001: A LOOK INTO THE REAL WORLD: PICTURE OF NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT INELIGIBLE TREATED PATIENTS IN THE FRONTLINE SETTING. CARINAE STUDY
por: de Arriba de la Fuente, F., et al.
Publicado: (2022)

Draft Genome Sequence of Enterococcus faecalis ATCC BAA-2128
por: Putonti, Catherine, et al.
Publicado: (2017)

2128. Murine Typhus and Pregnancy: Case Series and Literature Review
por: Tanabe, Melinda, et al.
Publicado: (2019)

Gaucher Disease for Hematologists
por: Özdemir, Gül Nihal, et al.
Publicado: (2022)

PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
por: Daver, N. G., et al.
Publicado: (2022)

PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA
por: Zhuang, Z., et al.
Publicado: (2022)

Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States
por: Medhekar, Rohan, et al.
Publicado: (2022)

PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Grosicki, Sebastian, et al.
Publicado: (2023)

Evaluation of How Integrative Oncology Services Are Valued between Hematology/Oncology Patients and Hematologists/Oncologists at a Tertiary Care Center
por: Hansra, D. M., et al.
Publicado: (2018)

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY
por: Facon, T., et al.
Publicado: (2022)

2128. Predictors of Post-Discharge Prophylactic Antibiotics Following Spinal Fusion
por: Warren, David K, et al.
Publicado: (2018)

PB2115: TRIAL IN PROGRESS: A RANDOMIZED PHASE II STUDY OF MB-CART2019.1 COMPARED TO STANDARD OF CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
por: Borchmann, P., et al.
Publicado: (2022)

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY
por: Weisel, K., et al.
Publicado: (2023)

Shoulder pain: a hematologist’s perspective
por: Jain, Ankur, et al.
Publicado: (2016)

The Prevention of Cisplatin-Induced Nephrotoxicity: A General Consensus Statement of a Group of Oncologist-Hematologists, Adult and Pediatric Nephrologists, Radiation Oncologists, Clinical Pathologists, Clinical Pharmacologists, and Renal Physiologists on Cisplatin Therapy in Cancer Patients
por: Ashrafi, Farzaneh, et al.
Publicado: (2022)

Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey
por: Mesa, Ruben A., et al.
Publicado: (2016)

Acquired von Willebrand syndrome: focused for hematologists
por: Franchini, Massimo, et al.
Publicado: (2020)

Acute Mesenteric Thrombosis: A Hematologist Perspective
por: Moiz, Bushra, et al.
Publicado: (2020)

Cancer associated thrombosis: Which lessons for the hematologist?
por: Noble, Simon
Publicado: (2018)

Vaccine uptake and barriers to vaccination among at-risk adult populations in the US
por: Kolobova, Irina, et al.
Publicado: (2022)

Burden of vaccine-preventable diseases among at-risk adult populations in the US
por: Kolobova, Irina, et al.
Publicado: (2022)

PB2003: REAL-WORLD DURATION OF USE AND DOSING FREQUENCY OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA IN THE U.S.
por: Fonseca, R., et al.
Publicado: (2022)

Universal iron fortification of foods: the view of a hematologist
por: Martins, José Murilo
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ktpbs62qe2ka8r9qf9fnb62n1h